Skip to main content
Journal cover image

Understanding the state of pharmacogenomic testing for thiopurine methyltransferase within a large health system.

Publication ,  Journal Article
Root, A; Johnson, R; McGee, A; Lee, H-J; Yang, S; Voora, D
Published in: Pharmacogenomics
April 2020

Aim: To investigate the current state of TPMT testing at a single-academic medical center. Methods: Single-center, retrospective chart review for patients newly prescribed a thiopurine. Data collection and evaluation included the prevalence and timing of TPMT testing, correct dosage adjustment if applicable, and incidence of myelosuppression. Results: 121 patients (71%) received TPMT testing. Out of the tested patients, 110 (90.9%) were designated as wild-type with normal metabolism. Dosing modification was appropriate in applicable patients. In unadjusted analysis, there was a lower incidence of myelosuppression among patients who were tested versus those who were not (16.5 vs 36.7%). Conclusion: Based on the study results, TPMT testing opportunities exist for nearly 30% of patients. Testing may reduce the incidence of myelosuppression.

Duke Scholars

Published In

Pharmacogenomics

DOI

EISSN

1744-8042

Publication Date

April 2020

Volume

21

Issue

6

Start / End Page

411 / 418

Location

England

Related Subject Headings

  • Retrospective Studies
  • Pharmacology & Pharmacy
  • Pharmacogenomic Testing
  • Pharmacogenetics
  • North Carolina
  • Middle Aged
  • Methyltransferases
  • Mercaptopurine
  • Male
  • Humans
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Root, A., Johnson, R., McGee, A., Lee, H.-J., Yang, S., & Voora, D. (2020). Understanding the state of pharmacogenomic testing for thiopurine methyltransferase within a large health system. Pharmacogenomics, 21(6), 411–418. https://doi.org/10.2217/pgs-2019-0148
Root, Adam, Randall Johnson, Ann McGee, Hui-Jie Lee, Siyun Yang, and Deepak Voora. “Understanding the state of pharmacogenomic testing for thiopurine methyltransferase within a large health system.Pharmacogenomics 21, no. 6 (April 2020): 411–18. https://doi.org/10.2217/pgs-2019-0148.
Root A, Johnson R, McGee A, Lee H-J, Yang S, Voora D. Understanding the state of pharmacogenomic testing for thiopurine methyltransferase within a large health system. Pharmacogenomics. 2020 Apr;21(6):411–8.
Root, Adam, et al. “Understanding the state of pharmacogenomic testing for thiopurine methyltransferase within a large health system.Pharmacogenomics, vol. 21, no. 6, Apr. 2020, pp. 411–18. Pubmed, doi:10.2217/pgs-2019-0148.
Root A, Johnson R, McGee A, Lee H-J, Yang S, Voora D. Understanding the state of pharmacogenomic testing for thiopurine methyltransferase within a large health system. Pharmacogenomics. 2020 Apr;21(6):411–418.
Journal cover image

Published In

Pharmacogenomics

DOI

EISSN

1744-8042

Publication Date

April 2020

Volume

21

Issue

6

Start / End Page

411 / 418

Location

England

Related Subject Headings

  • Retrospective Studies
  • Pharmacology & Pharmacy
  • Pharmacogenomic Testing
  • Pharmacogenetics
  • North Carolina
  • Middle Aged
  • Methyltransferases
  • Mercaptopurine
  • Male
  • Humans